Barclays Reaffirms Their Hold Rating on Kenvue, Inc. (KVUE)
In a report released today, Lauren Lieberman from Barclays maintained a Hold rating on Kenvue, Inc., with a price target of $19.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Lieberman covers the Consumer Defensive sector, focusing on stocks such as PepsiCo, Kimberly Clark, and Constellation Brands. According to TipRanks, Lieberman has an average return of 4.3% and a 57.52% success rate on recommended stocks.
Kenvue, Inc. has an analyst consensus of Hold, with a price target consensus of $19.40.
Based on Kenvue, Inc.’s latest earnings release for the quarter ending March 29, the company reported a quarterly revenue of $3.91 billion and a net profit of $474 million. In comparison, last year the company earned a revenue of $3.74 billion and had a net profit of $322 million
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KVUE in relation to earlier this year. Last month, Heather Howlett, the CFO & CAO of KVUE sold 3,700.00 shares for a total of $66,970.00.
Read More on KVUE:
Disclaimer & DisclosureReport an Issue
- Kenvue price target raised to $20 from $18 at UBS
- Filippo Falorni Reiterates Hold on Kenvue, Keeps Price Target Unchanged at $19 Amid Renewed Tylenol Litigation Risks
- Appeals court revives autism suits against Kenvue’s Tylenol, Bloomberg says
- Appeals court rules Kenvue must face Tylenol autism claims, Bloomberg says
- Kimberly-Clark price target raised to $110 from $100 at Wells Fargo
